Company News

Special Event of National Cancer Prevention and Control Awareness Week | Shanghai Health Action: "Love Your Liver" Large Scale liver Cancer Early Screening Public Welfare Activity at Minhang Xinzhuang Kangcheng Community is about to Launch

2024 / 04 / 10

启动会主KV_画板 1 .jpg

In order to implement the spirit of the "Healthy China 2030" Plan Outline, and implement the decision-making deployment of the Healthy China Strategy, Minhang District, as a pilot area of a closely knit national medical consortium, has launched the "Shanghai Health Action" with a new model of proactive service based health management as the core. This action integrates the concept of "active health" into the community's entire health cycle monitoring and precise intervention process. Through the multi-party linkage of community residents, family doctors, and Minhang Hospital affiliated with Fudan University, it effectively promotes the sinking and hierarchical implementation of health management in the community, guiding residents from "passive medical treatment" to "active health management".


Shanghai Health Action: "Love Your Liver" - Large Scale Public Welfare Activity


Under the guidance of the Minhang District Health Commission, Fudan University Affiliated Minhang Hospital actively coordinates resources from all parties and takes Kangcheng Community as a pilot to propose new ideas for the construction and development of a close medical consortium in Minhang District. It has organized and planned a large-scale liver cancer early screening public welfare activity - Shanghai Health Action "Love Your Liver", which will be held in Kangcheng Community, Minhang District from 9:00 to 11:30 a.m. on April 13, 2024.


Dunwill Medical actively supports this event and will provide community residents with convenient liver cancer screening services to help detect, diagnose, and treat liver cancer early, and achieve active liver health management.


肝癌海报_画板 1 .png


Pay More Attention and Share More Health Benefits


In this event, Dunwill Medical will provide the first-time free blood screening service for high-risk individuals of liver cancer (males over 40 years old, viral hepatitis, long-term excessive drinking, non-alcoholic fatty liver disease, liver cirrhosis caused by other reasons, family history of liver cancer, and any other factors). On the day of the free diagnosis, a limited number of 2000 cases will be tested, on a first come, first served basis.


This public welfare activity is expected to last for two months, during which time regular health services will be provided to community residents at the Xinzhuang Community Health Service Center. Residents can actively participate with their families based on on-site and community center announcements. If residents are found to have potential health risks through screening, they can quickly and conveniently enjoy priority diagnosis and treatment services through the green channel services provided by Minhang Hospital affiliated with Fudan University.


A Strong Team of Experts, Face-to-face with Experts


This event invited experts in various fields of chronic diseases from Minhang Hospital affiliated with Fudan University, including leaders in the fields of liver disease, cardiovascular and cerebrovascular diseases, endocrinology, etc. They have excellent medical skills and rich experience, and will provide professional health consultation and free services for community residents.


Recommended Liver Cancer Screening Methods


MiRNAs are a type of non coding small molecule RNA, and research has shown that the detection rate of liver cancer based on plasma seven miRNAs in the diagnosis of very early liver cancer is as high as 86.1%, which is 30% higher than the traditional biomarker AFP; The sensitivity and specificity for AFP negative liver cancer were 77.7% and 84.5%, respectively, which were significantly better than the detection of traditional biomarkers.


MiRNA7™as the first Class III liver cancer molecular detection product approved by the National Medical Products Administration (NMPA) in China, it won the second prize of the National Science and Technology Progress Award in 2020 and has been included in multiple authoritative guidelines and consensus such as the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition).


mirna海报-2024.png


Building a fair, accessible, high-quality, and efficient health management model is not only a challenge, but also an opportunity. By closely linking with community hospitals, strengthening cooperation with them through resource sharing, technological exchange, and other means, the "Shanghai Health Action" will improve the diagnosis and treatment level and health management ability of primary medical institutions, solidify important links in resident health management, and promote the formation of a comprehensive and full lifecycle health management service system.


We look forward to the official launch of the "Shanghai Health Action", which can provide patients with safe, effective, and convenient high-quality health services, effectively improve the medical quality experience and health well-being of the whole population, assist in the construction of "Healthy China 2030", and build a beautiful future of national health.